Laura Niklason

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Retrieved on: 
Friday, June 11, 2021
Medicine, Clinical medicine, Bad Homburg vor der Höhe, Membrane technology, Health care, Renal dialysis, Private providers of NHS services, Fresenius, Societates Europaeae, Laura Niklason, Hemodialysis, Dialysis

Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.

Key Points: 
  • Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.
  • Under a Distribution Agreement entered into in June 2018, Fresenius Medical Care obtained the exclusive global rights to commercialize Humacytes HAVs in the applications of vascular access for hemodialysis and peripheral arterial disease.
  • We are pleased to expand our partnership with Fresenius Medical Care, the worlds leading care provider for patients undergoing kidney replacement therapy, said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Fresenius Medical Care has a network of more than 4,000 dialysis centers worldwide, and cares for over 300,000 patients with end-stage renal failure.

Humacyte Receives 2021 Life Sciences Award from Triangle Business Journal

Retrieved on: 
Wednesday, May 26, 2021
Research Triangle, Geography of North Carolina, North Carolina, Laura Niklason, Cities in the United States, Raleigh, North Carolina, American City Business Journals, Durham, North Carolina

DURHAM, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the company has received a 2021 Life Sciences Award from the Triangle Business Journal.

Key Points: 
  • DURHAM, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the company has received a 2021 Life Sciences Award from the Triangle Business Journal.
  • The annual Triangle Business Journal awards program honors individuals and organizations in the Raleigh-Durham area that are blazing trails and breaking ground in the life sciences industry.
  • We are honored to receive the Triangle Business Journal's Life Sciences award and be named among a group of extraordinary organizations in North Carolina that are transforming the life sciences industry, said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Information on the Triangle Business Journals Life Sciences awards program and the complete list of winners can be found on the Triangle Business Journals website at: https://www.bizjournals.com/triangle/news/2021/05/21/2021-life-sciences-... .

Humacyte Appoints Dale Sander as Chief Financial Officer

Retrieved on: 
Wednesday, May 19, 2021
Employment, Economy, Laura Niklason, Chief financial officer, Officer, Articles

b'DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Dale Sander as Chief Financial Officer, Chief Corporate Development Officer and Treasurer, effective immediately.

Key Points: 
  • b'DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Dale Sander as Chief Financial Officer, Chief Corporate Development Officer and Treasurer, effective immediately.
  • Mr. Sander will succeed Doug Blankenship, who is stepping down from the role.\n\xe2\x80\x9cAs Humacyte moves toward becoming a public company, we are evolving and building out our leadership team,\xe2\x80\x9d said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • \xe2\x80\x9cDale has extensive financial leadership experience in publicly listed life sciences companies, having served as CFO of five life sciences companies.
  • Sander has been a director of Humacyte since 2015, and recently served as Humacyte\xe2\x80\x99s acting Chief Corporate Development Officer.\n\xe2\x80\x9cHumacyte is establishing a new biotechnology category of regenerative medicine capable of creating engineered human tissue replacements for patients,\xe2\x80\x9d said Mr. Sander.

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Thursday, March 11, 2021
Laura Niklason

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.

Key Points: 
  • DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.
  • On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (AHAC), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
  • Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.
  • The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

Retrieved on: 
Tuesday, January 12, 2021
Biotechnology, Surgery, Health, Clinical trials, Cardiology, Creationism, Laura Niklason, Branches of biology, Regenerative biomedicine, Tissue engineering, Niklasons, Regenerative medicine, Institute for Creation Research, Biology

Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST.

Key Points: 
  • Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST.
  • Dr. Niklason will present an overview of Humacytes groundbreaking regenerative medicine therapies, including the Companys late-stage clinical programs in vascular trauma repair and AV access for hemodialysis.
  • A live audio webcast of Dr. Niklasons presentation will be available at https://icrinc.touchcast.com/showtime/icr-conference/embed/cc5377f9-2ef3... , and an archived version will be available after the conference.
  • The four-day invitation-only event aims to gain insight into future trends and growth strategies, and to exchange ideas through meaningful networking.

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

Retrieved on: 
Monday, January 11, 2021
Laura Niklason, Branches of biology, Regenerative medicine, Biomedical engineering, Biology, Life sciences

DURHAM, N.C., Jan. 11, 2021 /PRNewswire/ --Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST.

Key Points: 
  • DURHAM, N.C., Jan. 11, 2021 /PRNewswire/ --Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST.
  • The annualJ.P.Morgan HealthcareConferenceis the largest and most informative healthcare investmentsymposiumin the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
  • With speakers from more than 400 public and private companies and 8,000 participants, the three-day invite only conference is the largest healthcare investment symposium of its kind.
  • Humacyte was co-founded in 2004 by Laura Niklason, M.D., Ph.D., a world leader in cellular therapies/regenerative medicine; biomedical engineer Dr. Shannon Dahl; and molecular biologist Dr. Juliana Blum.

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer

Retrieved on: 
Friday, November 20, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Laura Niklason, Scientists

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer.

Key Points: 
  • Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer.
  • Jeffrey Lawson MD, PhD has been appointed the newly established role of Chief Surgical Officer and Vice Chairman.
  • Dr. Laura Niklason, a world leader in tissue engineering and cellular therapies, founded Humacyte in 2004.
  • In taking on the CEO role at Humacyte, Dr. Niklason will depart her role as the Vice-Chair of Anesthesiology at Yale University.

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Retrieved on: 
Monday, March 2, 2020
Health, Biotechnology, Laura Niklason, Tissue engineering, Regenerative medicine, Branches of biology, Scientists, Biology

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, has been elected to the prestigious National Academy of Engineering (NAE).

Key Points: 
  • Humacyte, an innovator in biotechnology and regenerative medicine, announced today that company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, has been elected to the prestigious National Academy of Engineering (NAE).
  • Dr. Niklason was recognized for her major contributions to cardiovascular tissue engineering, lung regeneration and biomedical imaging.
  • Founded in 1964, NAE is an independent, nonprofit institution that provides engineering leadership in service to the nation.
  • It is immensely gratifying to see the distinguished National Academy of Engineering has recognized Laura for her tireless dedication to innovation and leadership in tissue engineering and cellular therapies, said Jeffrey H. Lawson, M.D., Ph.D., President and CEO of Humacyte.

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 7, 2019
Health, Biotechnology, Research, Science, General Health, Regenerative medicine, Draft:Humacyte, Stem cells, Laura Niklason, Regenerative biomedicine

Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 8, 2019 at 9:00 a.m. Pacific Time.

Key Points: 
  • Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 8, 2019 at 9:00 a.m. Pacific Time.
  • Humacyte, Inc., a privately held company founded by Dr. Laura E. Niklason, M.D., Ph.D., in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products.
  • Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery.
  • The companys proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient.